Evoke Pharma (EVOK) Stock Price, News & Analysis

Company Overview

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $4.51 to $4.60
• 50-Day Range: $4.19 to $7.08
• 52-Week Range: $3.54 to $17.40
• Volume: 11,250 shs
• Average Volume: 126,955 shs
• Market Capitalization: $6.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Evoke Pharma Stock Analysis - MarketRank™

Evoke Pharma scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Evoke Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evoke Pharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evoke Pharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evoke Pharma has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.43% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently increased by 288.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evoke Pharma does not currently pay a dividend.

Dividend Growth

Evoke Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.43% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently increased by 288.46%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for EVOK on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Evoke Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evoke Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Evoke Pharma is held by insiders.

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed this year?

Evoke Pharma's stock was trading at $12.6036 at the start of the year. Since then, EVOK shares have decreased by 63.6% and is now trading at $4.59.
View the best growth stocks for 2024 here.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) announced its quarterly earnings data on Tuesday, August, 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.21. The specialty pharmaceutical company earned $2.55 million during the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 308.49% and a negative net margin of 71.32%.

When did Evoke Pharma's stock split?

Evoke Pharma shares reverse split before market open on Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Evoke Pharma's major shareholders?

Evoke Pharma's top institutional investors include Corsair Capital Management L.P. (1.42%).
View institutional ownership trends.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVOK
• CUSIP: N/A
• CIK: 1403708
• Web: www.evokepharma.com
• Phone: (858) 345-1494
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($10.9936)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,790,000.00
• Net Margins: -71.32%
• Pretax Margin: -71.32%
• Return on Equity: -308.49%
• Return on Assets: -53.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $5.18 million
• Price / Sales: 1.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.95 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 1,490,000
• Free Float: 1,395,000
• Market Cap: $6.79 million
• Optionable: Not Optionable
• Beta: 0.36